Graypoint LLC Grows Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Graypoint LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,319 shares of the company’s stock after acquiring an additional 386 shares during the quarter. Graypoint LLC’s holdings in Eli Lilly and Company were worth $7,370,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. raised its holdings in shares of Eli Lilly and Company by 19.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after acquiring an additional 1,620 shares in the last quarter. Quent Capital LLC lifted its position in shares of Eli Lilly and Company by 5.3% in the 1st quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock worth $3,846,000 after purchasing an additional 249 shares during the period. W.H. Cornerstone Investments Inc. boosted its stake in shares of Eli Lilly and Company by 44.6% during the first quarter. W.H. Cornerstone Investments Inc. now owns 1,213 shares of the company’s stock valued at $944,000 after purchasing an additional 374 shares in the last quarter. Manchester Capital Management LLC increased its holdings in Eli Lilly and Company by 33.9% during the first quarter. Manchester Capital Management LLC now owns 4,049 shares of the company’s stock valued at $3,150,000 after buying an additional 1,025 shares during the period. Finally, Advisory Services Network LLC raised its stake in Eli Lilly and Company by 5.1% in the first quarter. Advisory Services Network LLC now owns 45,528 shares of the company’s stock worth $35,418,000 after buying an additional 2,225 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on LLY shares. Berenberg Bank increased their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Citigroup raised their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research report on Friday, October 25th. BMO Capital Markets lifted their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, Barclays cut their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,008.41.

Eli Lilly and Company Trading Down 3.7 %

Eli Lilly and Company stock opened at $776.47 on Thursday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 52 week low of $561.65 and a 52 week high of $972.53. The company has a market capitalization of $737.11 billion, a price-to-earnings ratio of 83.94, a price-to-earnings-growth ratio of 3.05 and a beta of 0.43. The stock has a 50-day moving average price of $901.75 and a 200 day moving average price of $867.32.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s revenue was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.10 earnings per share. Sell-side analysts anticipate that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.